The aim of this research was to investigate the correlation of immunologic factors in the tumor environment of breast cancer, using immunohistological staining to evaluate the expression of programmed death 1/programmed death ligand 1 ( PD ‐1/ PD ‐L1), phosphatase and tensin homolog ( PTEN ), tumor infiltrating lymphocytes ( TIL s), and macrophages, and to analyze the association between the immunologic factors and clinical outcome for patients with early stage breast cancer ( EBC ). A total of 97 EBC patients who underwent standard surgery were investigated. Expression of PD ‐1/ PD ‐L1 and PTEN and the density of CD 3 + TIL s, CD 8 + TIL s, and CD 163 + macrophages were evaluated by immunohistochemical analysis. The association between the immunologic factors and clinical outcome was statistically analyzed. The density of CD 3 + TIL s, CD 8 + TIL s, and CD 163 + macrophages and non‐expression of PTEN was significantly higher in cases of triple negative breast cancer. CD 8 + TIL density and CD 8 + / PD ‐L1 + expression were predictive factors for disease‐free survival and overall survival ( OS ). Human epidermal growth factor 2 ( HER 2)‐positive patients with PTEN expression and luminal/ HER 2‐negative patients without PD ‐L1 expression had significantly longer OS compared to patients without PTEN expression ( P = 0.049) and with PD ‐L1 expression ( P = 0.036), respectively. Furthermore, patients with PD ‐L1 + / CD 8 + expression had worse median progression‐free survival ( P = 0.022) and median OS ( P = 0.037) compared with patients without PD ‐L1 + / CD 8 + expression. The CD 3 + TIL s, CD 8 + TIL s, and CD 163 + macrophages were shown to infiltrate the tumor area of EBC . In particular, triple negative breast cancer had a higher rate of TIL infiltration within the tumor environment. Expression of PTEN and lack of PD ‐L1 expression were associated with favorable survival in HER 2‐positive and luminal/ HER 2‐negative EBC patients, respectively. The PD ‐L1 expression combined with CD 8 + density was significantly associated with an aggressive clinical outcome.
No takes yet. Share an insight, caveat, or question.
Okabe et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: